<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04570787</url>
  </required_header>
  <id_info>
    <org_study_id>04/20-Ð½</org_study_id>
    <nct_id>NCT04570787</nct_id>
  </id_info>
  <brief_title>Bladder Catheterization After Mini-PCNL</brief_title>
  <official_title>Single-center Randomized Study Evaluating Feasibility of Routine Bladder Catheterization After Mini- Percutaneous Nephrolithotripsy (PCNL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Petersburg State Pavlov Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Petersburg State Pavlov Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      60 patients&#xD;
&#xD;
      Inclusion Criteria:&#xD;
&#xD;
        -  age from 18 to 70 years&#xD;
&#xD;
        -  Indications for mini-PCNL&#xD;
&#xD;
        -  ASA score: 1-3&#xD;
&#xD;
        -  Single percutaneous access to pyelocaliceal system&#xD;
&#xD;
        -  Size of solitary calculus up to 2.5 cm&#xD;
&#xD;
      Exclusion Criteria:&#xD;
&#xD;
        -  Active urinary tract infection&#xD;
&#xD;
        -  Coagulopathy&#xD;
&#xD;
        -  Clinically significant infravesical obstruction (Qmax less than 10 ml / s, PVR more than&#xD;
           50 ml)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      60 patients after PCNL will be recruited and randomized into 2 groups (30 vs 30):&#xD;
&#xD;
        -  No Catheterization after mini-PCNL (study) - the bladder catheterization is not&#xD;
           performed.&#xD;
&#xD;
        -  Catheterization after mini-PCNL (control) - the bladder will be drained with the&#xD;
           urethral catheter.&#xD;
&#xD;
      All patients will fill out the VASP in 2, 6, 12, 24 hours after mini-PCNL. Ultrasound&#xD;
      examination of urinary bladder will be performed after mini-PCNL. All the AE will be&#xD;
      registered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To measure the level of pain in patients</measure>
    <time_frame>1 day</time_frame>
    <description>Filling out the VASP score after PCNL by all patients in 2, 6, 12 and 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To register the AE regarding catheterization or absence of catheterization</measure>
    <time_frame>1 day</time_frame>
    <description>Performing ultrasound examination of urinary bladder after PCNL,</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Urolithiasis</condition>
  <arm_group>
    <arm_group_label>No Catheterization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After mini-PCNL standardized follow-up protocol supposes drainage the upper urinary tract with nephrostomy, tubeless (using ureteral stent without nephrostomy) or totally tubeless (no drainage) tactics. Bladder catheterization is not performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Catheterization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After mini-PCNL standardized follow-up protocol supposes drainage the upper urinary tract with nephrostomy, tubeless (using ureteral stent without nephrostomy) or totally tubeless (no drainage) tactics. The bladder is to be drained with the urethral catheter in all cases.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Urinary bladder catheterisation</intervention_name>
    <description>Installation of Foley catheter into the urinary bladder</description>
    <arm_group_label>Catheterization</arm_group_label>
    <arm_group_label>No Catheterization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 70 years&#xD;
&#xD;
          -  Indications for mini-PCNL&#xD;
&#xD;
          -  ASA score: 1-3&#xD;
&#xD;
          -  Single percutaneous access to pyelocaliceal system&#xD;
&#xD;
          -  Size of solitary stone up to 2.5 cm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active urinary tract infection&#xD;
&#xD;
          -  Coagulopathy&#xD;
&#xD;
          -  Clinically significant infravesical obstruction (Qmax less than 10 ml / s, PVR more&#xD;
             than 50 ml)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dmitry S Gorelov</last_name>
    <phone>+79217964892</phone>
    <email>dsgorelov@mail.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vladimir M Obidniak</last_name>
    <phone>+79218944746</phone>
    <email>v.obidniak@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Pavlov Saint Petersburg University</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197342</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmitriy Gorelov, MD</last_name>
      <phone>+79217964892</phone>
      <email>dsgorelov@mail.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 5, 2020</study_first_submitted>
  <study_first_submitted_qc>September 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urolithiasis</keyword>
  <keyword>PCNL</keyword>
  <keyword>Bladder catheterisation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urolithiasis</mesh_term>
    <mesh_term>Urinary Calculi</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

